SCHEMBL22200719

SCHEMBL22200719

CC(C)n1c(=O)c(-c2cc(F)c(NSCCC(F)(F)F)c(F)c2)nc2cnc(N)nc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 3/20 0.42
MTOR P42345 4/20 0.35
CYP1A2 P05177 11/20 0.34
HSD17B10 Q99714 8/20 0.34
ALDH1A1 P00352 7/20 0.34
CASP1 P29466 6/20 0.34
CASP7 P55210 6/20 0.34
MEN1 O00255 5/20 0.34
KMT2A Q03164 5/20 0.34
USP2 O75604 5/20 0.34
HIF1A Q16665 3/20 0.34
GLA P06280 1/20 0.34
CLK4 Q9HAZ1 1/20 0.34
CYP3A4 P08684 6/20 0.32
CYP2D6 P10635 3/20 0.32
HPGD P15428 2/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
RORC P51449 1/20 0.32
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22200355 0.89 ERN1 (0.41) ERN1MTORCYP1A2HSD17B10ALDH1A1
SCHEMBL22200656 0.89 ERN1 (0.48) ERN1CYP1A2HSD17B10ALDH1A1CASP1
SCHEMBL22200574 0.86 ERN1 (0.34) ERN1MTORRORC
SCHEMBL22200627 0.85 ERN1 (0.52) ERN1MTORCYP1A2HSD17B10ALDH1A1
SCHEMBL22200393 0.84 RORC (0.34) ERN1MTORRORCPIK3CA
SCHEMBL22200392 0.84 ERN1 (0.33) ERN1MTORRORC
SCHEMBL25034211 0.83 ERN1 (0.52) ERN1MTORCYP1A2HSD17B10ALDH1A1
SCHEMBL22200635 0.83 ERN1 (0.39) ERN1CYP1A2HSD17B10ALDH1A1CASP1
SCHEMBL22200788 0.83 USP2 (0.40) ERN1CYP1A2HSD17B10ALDH1A1CASP1
SCHEMBL22200658 0.83 ERN1 (0.44) ERN1MTORCYP1A2HSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020142612-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. GENENTECH, INC. (US) 2020-07-09 WO disclosed